Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis.
Mitoxantrone is one of the few drugs approved for the treatment of progressive multiple sclerosis (MS). However, the prolonged use of this potent immunosuppressive agent is limited by the appearance of severe side effects. Apart from its general cytotoxic effect, the mode of action of mitoxantrone o...
Main Authors: | Coralie Chanvillard, Jason M Millward, Marta Lozano, Isabell Hamann, Friedemann Paul, Frauke Zipp, Jan Dörr, Carmen Infante-Duarte |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22768101/?tool=EBI |
Similar Items
-
Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany
by: Anke Stroet, et al.
Published: (2012-03-01) -
The role of natural killer cells in multiple sclerosisand their therapeutic implications
by: Coralie eChanvillard, et al.
Published: (2013-03-01) -
Treatment of Chronic Experimental Autoimmune Encephalomyelitis with Epigallocatechin-3-Gallate and Glatiramer Acetate Alters Expression of Heme-Oxygenase-1.
by: Antonia Janssen, et al.
Published: (2015-01-01) -
Running a mitoxantrone service for multiple sclerosis
by: Craner, M, et al.
Published: (2006) -
Neuroprotective effect of combination therapy of glatiramer acetate and epigallocatechin-3-gallate in neuroinflammation.
by: Katja Herges, et al.
Published: (2011-01-01)